The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Impact of ApoB-100 expression on cognition and brain pathology in wild-type and hAPPsl mice
Abstract
During their lifetime, people are commonly exposed to several vascular risk factors that may affect brain ageing and cognitive function. In the last few years, increasing evidence suggests that pathological plasma lipid profiles contribute to the pathogenesis of late-onset Alzheimer's disease. Importantly, hypercholesterolemia, especially elevated low-density lipoprotein cholesterol values, that is, increased apolipoprotein B-100 (ApoB-100) levels, represents an independent risk factor. In this study, the effects of ApoB-100 overexpression, either alone or in combination with cerebral expression of human amyloid precursor protein (hAPP), on cognitive functions and brain pathology were assessed. Our results show that ApoB-100 overexpression induces memory decline and increases cerebral lipid peroxidation and amyloid beta levels compared to those in wild-type animals. Although double-transgenic ApoBxAPP animals did not develop more distinct behavioral deficits than single-transgenic hAPP littermates, hApoB-100 expression caused additional pathophysiological features, such as high LDL and low HDL-cholesterol levels, increased lipid peroxidation, and pronounced ApoB-100 accumulation in cerebral vessels. Thus, our results indicate that ApoBxAPP mice might better reflect the situation of elderly humans than hAPPsl overexpression alone.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ApoB has been detected in the brain parenchyma of hypercholesterolemic animals.
“Indeed, apolipoprotein B (ApoB), the primary protein component of LDL, has been detected in the brain parenchyma of hypercholesterolemic animals, suggesting that LDL influx is a key pathological consequence of BBB breakdown (Chen et al. 2010; Löffler et al. 2013).”
From LDL Cholesterol Modulates Astrocyte Metabolism, Lipid Handling, and Morphology: Evidence From In Vitro and In Vivo Models (2026) · cites this paper as Löffler et al. 2013
Citations
Cites
Cerebral microvascular pathology in aging and Alzheimer's disease
Farkas, E., & Luiten, P. G. M. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00068-x · Cited by 1,102
Amyloid-β is an antioxidant for lipoproteins in cerebrospinal fluid and plasma
Kontush, A., Berndt, C., Weber, W., Akopyan, V., Arlt, S., Schippling, S., & Beisiegel, U. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00458-5 · Cited by 180 · cited 1×
“, 2002) and to inhibit oxidation of CSF lipoproteins and plasma LDL (Kontush et al., 2001).”
BackgroundEnhanced brain levels of 8,12- iso -iPF 2α -VI differentiate AD from frontotemporal dementia
Yao, Y., Zhukareva, V., Sung, S., Clark, C. M., Rokach, J., Lee, V. M.-Y., Trojanowski, J. Q., & Praticò, D. (2003) · Neurology · doi:10.1212/01.wnl.0000070185.02546.5d · Cited by 86
Flagged first, then by citations
Research works printed but not linked: 29
- Bereczki, 2008, Overexpression of human apolipoprotein B-100 induces severe neurodegeneration in transgenic mice, J. Proteome Res., 7, 2246, 10.1021/pr7006329 · DOI · Paper page
- Bjelik, 2006, Human apoB overexpression and a high-cholesterol diet differently modify the brain APP metabolism in the transgenic mouse model of atherosclerosis, Neurochem. Int., 49, 393, 10.1016/j.neuint.2006.01.026 · DOI
- Bonomini, 2008, Atherosclerosis and oxidative stress, Histol. Histopathol., 23, 381
- Breslow, 1996, Mouse models of atherosclerosis, Science, 272, 685, 10.1126/science.272.5262.685 · DOI · Paper page
- Burns, 2002, Alzheimer's disease, Lancet, 360, 163, 10.1016/S0140-6736(02)09420-5 · DOI
- Callow, 1994, Expression of human apolipoprotein B and assembly of lipoprotein(a) in transgenic mice, Proc. Natl. Acad. Sci. U.S.A., 91, 2130, 10.1073/pnas.91.6.2130 · DOI
- Callow, 1995, Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a), J. Clin. Invest., 96, 1639, 10.1172/JCI118203 · DOI
- Corder, 1993, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families, Science, 261, 921, 10.1126/science.8346443 · DOI · Paper page
- Ferri, 2005, Global prevalence of dementia: a Delphi consensus study, Lancet, 366, 2112, 10.1016/S0140-6736(05)67889-0 · DOI
- Frisoni, 2010, The clinical use of structural MRI in Alzheimer disease, Nat. Rev. Neurol., 6, 67, 10.1038/nrneurol.2009.215 · DOI · Paper page
- Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994 · DOI · Paper page
- Harman, 2006, Alzheimer's disease pathogenesis: role of aging, Ann. N. Y. Acad. Sci., 1067, 454, 10.1196/annals.1354.065 · DOI
- Havas, 2011, A longitudinal study of behavioral deficits in an AbetaPP transgenic mouse model of Alzheimer's disease, J. Alzheimers Dis., 25, 231, 10.3233/JAD-2011-101866 · DOI
- Humpel, 2011, Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease?, Exp. Gerontol., 46, 225, 10.1016/j.exger.2010.11.032 · DOI
- Jarvik, 1995, Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study, Neurology, 45, 1092, 10.1212/WNL.45.6.1092 · DOI
- Kowalska, 2004, [The beta-amyloid cascade hypothesis: a sequence of events leading to neurodegeneration in Alzheimer's disease], Neurologia i neurochirurgia polska, 38, 405
- Kuo, 1998, Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels, Biochem. Biophys. Res. Commun., 252, 711, 10.1006/bbrc.1998.9652 · DOI · Paper page
- Lenart, 2012, Increased tau phosphorylation and impaired presynaptic function in hypertriglyceridemic ApoB-100 transgenic mice, PLoS One, 7, e46007, 10.1371/journal.pone.0046007 · DOI
- Markesbery, 2005, Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment, Ann. Neurol., 58, 730, 10.1002/ana.20629 · DOI
- Martins, 2009, Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease, J. Neurochem., 111, 1275, 10.1111/j.1471-4159.2009.06408.x · DOI
- Miyakawa, 2010, Vascular pathology in Alzheimer's disease, Psychogeriatrics, 10, 39, 10.1111/j.1479-8301.2009.00294.x · DOI
- Morris, 1984, Developments of a water-maze procedure for studying spatial learning in the rat, J. Neurosci. Methods, 11, 47, 10.1016/0165-0270(84)90007-4 · DOI · Paper page
- Rockenstein, 2001, Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1–42), J. Neurosci. Res., 66, 573, 10.1002/jnr.1247 · DOI
- Skoog, 1999, Vascular factors and Alzheimer disease, Alzheimer Dis. Assoc. Disord., 13, S106, 10.1097/00002093-199912003-00016 · DOI
- Sparks, 2000, Link between heart disease, cholesterol, and Alzheimer's disease: a review, Microsc. Res. Techn., 50, 287, 10.1002/1097-0029(20000815)50:4<287::AID-JEMT7>3.0.CO;2-L · DOI
- Sule, 2009, Capillary injury in the ischemic brain of hyperlipidemic, apolipoprotein B-100 transgenic mice, Life Sci., 84, 935, 10.1016/j.lfs.2009.04.011 · DOI
- Tanzi, 2001, New frontiers in Alzheimer's disease genetics, Neuron, 32, 181, 10.1016/S0896-6273(01)00476-7 · DOI
- Walsh, 2002, Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition, Biochem. Soc. Trans., 30, 552, 10.1042/bst0300552 · DOI
- Zou, 2002, A novel function of monomeric amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage, J.Neurosci., 22, 4833, 10.1523/JNEUROSCI.22-12-04833.2002 · DOI · Paper page
Cited by
Sorted by citations
Wingo, T. S., Cutler, D. J., Wingo, A. P., Le, N.-A., Rabinovici, G. D., Miller, B. L., Lah, J. J., & Levey, A. I. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.0648 · Cited by 119
Baumart, G. J., Rodrigues, M. S., Sholl, J. N., de Sousa, A. C., Weber, A. F., Costa‐Beber, L. C., Farias, H. R., Costa, M. V., Peres, A. M., de Camargo, P. R., et al. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70403 · Cited by 2
Metadata
- Authors
- Löffler, T., Flunkert, S., Havas, D., Sántha, M., Hutter-Paier, B., Steyrer, E., & Windisch, M.
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 34
- Issue
- 10
- Pages
- 2379-2388
- ISSN
- 0197-4580
- Cited by
- 42
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review